Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448579 | 0.84 | IDO1 (0.31) | IDO1TDO2 | |
| SCHEMBL31448548 | 0.83 | P2RX3 (0.50) | P2RX3P2RX2IDO1TDO2 | |
| SCHEMBL31448434 | 0.78 | KDM4E (0.33) | P2RX3P2RX2KDM4EMAPTCRHBP | |
| SCHEMBL31448578 | 0.78 | KDM4E (0.37) | KDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL30772402 | 0.78 | MEN1 (0.38) | P2RX3P2RX2 | |
| SCHEMBL31448547 | 0.77 | CXCL8 (0.44) | KDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL31448589 | 0.77 | HTR2A (0.33) | KDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL30772401 | 0.74 | L3MBTL1 (0.35) | MAPT | |
| SCHEMBL25733524 | 0.74 | HTR7 (0.41) | IDO1KDM4EMAPT | |
| SCHEMBL31448640 | 0.74 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4512801-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | Kissei Pharmaceutical Co., Ltd. (JP) | 2025-02-26 | — | — | EP | disclosed |
| CN-119343332-A | 3, 4-Dihydro-quinolin-2 (1H) -one compounds | 橘生药品工业株式会社 | 2025-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | P2RX3 2962/4885P2RX2 3183/4885IDO1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.